FAQ/Help |
Calendar |
Search |
Today's Posts |
11-26-2008, 02:49 PM | #1 | |||
|
||||
Senior Member
|
SAN DIEGO, Nov 26, 2008 /PRNewswire via COMTEX/ -- Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. The trial did not demonstrate an appreciable difference between patients treated with CERE-120 versus those in the control group. Both groups showed an approximate 7 point improvement in the protocol-defined primary endpoint (Unified Parkinson's Disease Rating Scale- motor off score at 12 months), relative to a mean at baseline of approximately 39 points. Both groups had a substantial number of patients who demonstrated a meaningful clinical improvement from baseline. CERE-120 appeared to be safe and well tolerated.
(the entire article)
__________________
Jean B This isn't the life I wished for, but it is the life I have. So I'm doing my best. |
|||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Six-Month Efficacy Results With Low Dose of ProSavin in Phase I/II Trial | Parkinson's Disease | |||
Ceregene Awaits Parkinson’s Trial Results, In a Key Test for Gene Therapy (CERE-120) | Parkinson's Disease | |||
Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's D | Parkinson's Disease | |||
Cere 120 clinical trial | Parkinson's Disease | |||
CERE-120 Phase II trials fall of 2006 | Parkinson's Disease |